Amivantimab versus real-world clinical practice in Europe and the US for patients with advanced non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations

Girard N, Wolf J, Kron A, Scheffler M, Knott CS Bosquet L et al. Amivantimab versus real-world clinical practice in Europe and the US for patients with advanced non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations. ISPOR Europe 2022; 2022 Nov 6-9.